Rb, 7 ml RTU

Technische Daten
Reaktivität AK:Human, others not tested.
Format AK:Ready-to-use
Ig Unterklasse:IgG
Immunogen:Synthetic peptide of human Mesothelin C-terminal
Anwendung AK:IHC(p),IHC(f)
Fixierung:1) NOTOXhisto 2) Formalin
Lagerung AK:Store at 2 - 8 °C. Do not use after expiration date indicated on the vial.
Zelluläre Lokalisation:Membranous, cytoplasmic
Synonyme:Mesothelin, MLSN, MES, CAK 1, CAK1, CAK1 antigen, Megakaryocyte potentiating factor, Mesothelin isoform 1 precursor, MPF, MSLN, Pre pro megakaryocyte potentiating factor, SMR, SMRP, Soluble MPF mesothelin related protein.
Verfügbar in folgenden Ländern:world wide (except US)

Mesothelin is not well known, but may play a role in cell adhesion and cell shape dynamics. It is present on normal mesothelial cells lining the pleura, peritoneum, and pericardium. In tumors, overexpression has been observed in mesotheliomas, and other tumors including ovarian, pancreatic carcinomas, and cholangiocarcinoma.


[1] Argani P, Iacobuzio-Donahue C, Ryu BClin et al. (2001): Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE). Cancer Res. 7(12):3862-8.
[2] Cao D, Ji H and Ronnett BM (2005): Expression of mesothelin, fascin, and prostate stem cell antigen in primary ovarian mucinous tumors and their utility in differentiating primary ovarian mucinous tumors from metastatic pancreatic mucinous carcinomas in the ovary. Int J Gynecol Pathol. 24(1):67-72.
[3] Hassan R and Ho M (2007): Mesothelin targeted cancer immunotherapy. Eur J Cancer. 44(1):46-53.
[4] Ord—–ez NG (2003): Value of mesothelin immunostaining in the diagnosis of mesothelioma. Mod Pathol. 16(3):192-7.
[5] Sathyanarayana BK, Hahn Y, Patankar MS et al. (2009): Mesothelin, Stereocilin, and Otoancorin are predicted to have superhelical structures with ARM-type repeats. BMC Struct Biol. 9:1.
[6] Chang K and Pastan I (1996): Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. Proc Natl Acad Sci U S A. 93(1):136-40.
[7] Chang K, Pastan I and Willingham MC (1992): Isolation and characterization of a monoclonal antibody, K1, reactive with ovarian cancers and normal mesothelium. Int J Cancer. 50(3):373-81.